induction cisplatin

Phase 2Small molecule

induction cisplatin is one of 99 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Bladder CancerActive, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Bladder CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Preclinical

72 2

Lenvima

Eisai

Preclinical

6 3

Gilotrif

Boehringer Ingelheim

Preclinical

12 4

induction cisplatin

Radiation Therapy Oncology Group

Phase 2

1 5

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 6

Remeron

OOrganon and Co

Preclinical

1 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 8

REGN2810

Regeneron

Preclinical

1 9

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Vidaza

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00096226·60 enrolled

Bladder Cancer1 trial

Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00777491·70 enrolled

Nasopharyngeal Carcinoma1 trial

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Recruiting·WWei Jiang·Phase 2·NCT05097209·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for induction cisplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — induction cisplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for induction cisplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Radiation Therapy Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Radiation Therapy Oncology Group

induction cisplatin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Bladder Cancer1 trial

Nasopharyngeal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News